<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631667</url>
  </required_header>
  <id_info>
    <org_study_id>LPI-8554</org_study_id>
    <secondary_id>R01ES028600</secondary_id>
    <nct_id>NCT03631667</nct_id>
  </id_info>
  <brief_title>Ultralow Dose PAH Binary Mixture Study</brief_title>
  <official_title>Ultralow Dose PAH Binary Mixture Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lawrence Livermore National Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pacific Northwest National Laboratory</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in&#xD;
      plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng&#xD;
      phenanthrene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics for [14C]-BaP and metabolites will be assessed by UHLPC-Accelerator Mass&#xD;
      Spectrometry (AMS, Lawrence Livermore National Laboratory) in plasma and urine collected over&#xD;
      48 hours following oral doses of 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.&#xD;
      Metabolite profiles and kinetics of elimination are predicted to be consistent with a BaP&#xD;
      physiologically based pharmacokinetic (PBPK) model developed by Pacific Northwest National&#xD;
      Laboratory (PNNL). A non-smoker, not exposed occupationally, receives 270-700 ng of BaP&#xD;
      daily; about 95% dietary. The WHO has set an estimated safe daily lifetime (70 year/70 Kg&#xD;
      individual, cancer endpoint) exposure to BaP of 42-350 ng. This protocol represents de&#xD;
      minimus risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Deidentified samples will be analyzed by AMS at Lawrence Livermore National Laboratory and the pharmacokinetics determine at Pacific Northwest National Laboratory.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine 14C-BaP and 14C-BaP metabolite levels after oral dose</measure>
    <time_frame>48 hours</time_frame>
    <description>Plasma and urine levels of 14C-BaP and 14C-BaP metabolites measured by accelerator mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of 14C-BaP Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of highest concentration of 14C-BaP in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at highest plasma concentration of 14C-BaP Tmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of time at which plasma concentration of 14C-BaP is highest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration of 14C-BaP versus time curve AUC</measure>
    <time_frame>48 hours</time_frame>
    <description>Integration of concentration of 14C-BaP in plasma over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of elimination of 14C-BaP</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of constants for rate of elimination of 14C-BaP from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of 14C-BaP in plasma</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of plasma metabolites of 14C-BaP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of 14C-BaP in urine</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of urinary metabolites of 14C-BaP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Environmental Exposure</condition>
  <arm_group>
    <arm_group_label>50 ng dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 ng dose plus 1250 ng phenanthrene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-benzo[a]pyrene</intervention_name>
    <description>Oral micro-dose (50 ng) (5.4 nCi)</description>
    <arm_group_label>50 ng dose</arm_group_label>
    <other_name>Carcinogenic PAH environmental pollutant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-benzo[a]pyrene plus phenanthrene</intervention_name>
    <description>Oral micro-dose of 50 ng (5.4 nCi) [14C]-benzo[a]pyrene plus 1250 ng phenanthrene</description>
    <arm_group_label>50 ng dose plus 1250 ng phenanthrene</arm_group_label>
    <other_name>Binary mixture of carcinogenic PAH and non-carcinogenic PAH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21-65 (inclusive)&#xD;
&#xD;
          -  If female, must be post-menopausal or have had surgical sterilization to eliminate any&#xD;
             possibility for fetal exposure&#xD;
&#xD;
          -  Willing to defer blood donation for one month before, throughout, and one month after&#xD;
             completion of study activities&#xD;
&#xD;
          -  Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or&#xD;
             cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each&#xD;
             study cycle (gas grilled foods acceptable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker (tobacco or other substances) or use of smokeless tobacco in past 3 months or&#xD;
             living with smoker&#xD;
&#xD;
          -  Regular use of medications that affect gut motility or nutrient absorption (e.g.&#xD;
             cholestyramine, sucralfate, orlistat, pro- or anti-motility agents)&#xD;
&#xD;
          -  History of gastrointestinal surgery (e.g. bariatric surgery, cholecystectomy) or&#xD;
             gastrointestinal disorder (Crohn's disease, celiac disease, IBS, or colitis)&#xD;
&#xD;
          -  Current or history of kidney or liver disease&#xD;
&#xD;
          -  Prior high-dose 14C exposure from medical tests. (micro-dose 14C exposure not&#xD;
             exclusionary)&#xD;
&#xD;
          -  Occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.)&#xD;
&#xD;
          -  Regular use of indole-3-carbinol or DIM dietary supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon State University</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon State University</investigator_affiliation>
    <investigator_full_name>David Williams</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Benzo[a]pyrene</keyword>
  <keyword>Accelerator Mass Spectrometry</keyword>
  <keyword>Polycyclic Aromatic Hydrocarbons</keyword>
  <keyword>Phenanthrene</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Deidentified samples sent to Lawrence Livermore National Laboratory Deidentified data sent to Pacific Northwest National Laboratory</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

